|
|
 Home 
What is Buprenorphine?
DATA Physician Locator
DATA 2000
FAQs
Publications/Reports
Links
En Español
 Physician Waiver Qualifications
Waiver Notification Form
Upcoming Trainings
Waived Physician WebBoard
Update Physician Contact Information
Model State Medical Board Policy
 Email Us |
The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the Controlled Substances Act. more 
Federal Register NoticeThe Office of Management and Budget seeks comment on the information collection burden as part of the process to renew the information collection authorization for "Form SMA-167: Notification of Intent to Use Schedule III, IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate Addiction." The closing date for comments is January 5, 2009. Use this link to view the notice.Results from New Clinical Trial of Buprenorphine in Young AdultsThis clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12 weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioid-poisitive urine test results at weeks 4 and 8 but not at week 12. Click here for link to JAMA Article.SAMHSA and NIDA Convene Summit on Buprenorphine TreatmentThe Summit convened February 21-22, 2008, in Washington, D.C. to bring together experts in epidemiology, pharmacology, toxicology, and addiction treatment in order to build upon the findings of the previous summits in 2003 and 2005. Participants assessed the successes, progress and continued barriers to access to opioid treatment with buprenorphine. Presentations identified best practices and useful clinical supports to enhance the quality of treatment. Participants identified strategies to address emerging issues and concerns. SAMHSA and NIDA will prepare a report on the proceedings.Use this HTML link to view presentations.Update Physician Contact InformationPhysicians, you can now update your own contact information. If you have given permission to post contact information in the Buprenorphine Physician and Treatment Program Locator, the information will be updated there too. Use this link to go to the update form.
|
 Treatment Improvement Protocol Increase Patient Limits 2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program 2006 Report On Diversion and Abuse of Buprenorphine Drug Enforcement Administraton (DEA) DATA Physician Locator  CSAT Director Informs Physicians of Increase in Patient Limits CSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program Locator CSAT Director Advises Physicians of Concerns Regarding Buprenorphine CSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator Follow this RealMedia link to view a Public Service Announcement (PSA) on office-based opioid addiction treatment featuring former Surgeon General Dr. C. Everett Koop. [Realplayer file, need Realplayer to review] If you do not have RealPlayer, you may download a free copy from Real Networks. |
 |
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov * Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program. |
 |
